A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological
effects of PRMT5 inhibitor, GSK3326595, in Early Stage Breast Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
GlaxoSmithKline Hamilton Health Sciences Corporation London Regional Cancer Program, Canada Ontario Institute for Cancer Research